Finanzen von AngioDynamics, Inc. (ANGO)ANGOAngioDynamics, Inc.

AngioDynamics, Inc. (ANGO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Med Device, accounting for 51.8% of total sales, equivalent to $44.85M. Another important revenue stream is Med Tech. Understanding this composition is critical for investors evaluating how ANGO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, AngioDynamics, Inc. maintains a gross margin of 56.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6.33%, while the net margin is -8.77%. These profitability ratios, combined with a Return on Equity (ROE) of -19.21%, provide a clear picture of how effectively ANGO converts its operational activities into shareholder value.

In the context of the broader market, ANGO competes directly with industry leaders such as DCTH and SGHT. With a market capitalization of $500.03M, it holds a significant position in the sector. When comparing efficiency, ANGO's gross margin of 56.00% stands against DCTH's 89.75% and SGHT's 90.96%. Such benchmarking helps identify whether AngioDynamics, Inc. is trading at a premium or discount relative to its financial performance.

AngioDynamics has reported fluctuating revenues, with Q4 2026 revenue at $86.6 million, but has consistently incurred losses, with a net income loss of $11.4 million in Q4 2026. The gross margin has improved to 50.87% in Q4 2026, showing some operational efficiency.